Publications by authors named "Amy Cutrell"

Claim this Profile
E
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Chloe Orkin, Jonathan M Schapiro, Carlo F Perno, Daniel R Kuritzkes, Parul Patel, Amy G Cutrell

Clin Infect Dis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project.
Neil Parkin, Fei Gao, Eduard Grebe, Amy Cutrell, Moupali Das

Clin Pharmacol Ther· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
Ronald D'Amico, Santiago Cenoz Gomis, Riya Moodley, Rodica Van Solingen-Ristea, Bryan Baugh, Amy Cutrell

HIV Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
Kelong Han, Mark Baker, Mark Lovern, Prokash Paul, Yuan Xiong, Amy G Cutrell

Br J Clin Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Hans Jaeger, Catherine Orrell, Amy Cutrell

Lancet· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Chloe Orkin, Enrique Bernal Morell, Darrell H S Tan, Harold Katner, Hans-Jürgen Stellbrink, Amy Cutrell

Lancet HIV· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
Amy G Cutrell, Jonathan M Schapiro, Carlo F Perno, Daniel R Kuritzkes, Romina Quercia

AIDS· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Chloe Orkin, Shinichi Oka, Patrick Philibert, Cynthia Brinson, Ayesha Bassa, Amy Cutrell

Lancet HIV· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
Giuliano Rizzardini, Edgar T Overton, Chloe Orkin, Susan Swindells, Keikawus Arasteh, Amy Cutrell

J Acquir Immune Defic Syndr· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
Lisa L Ross, A Sarah Walker, Yu Lou, Allan R Tenorio, Diana M Gibb, Amy Cutrell

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Chloe Orkin, Keikawus Arasteh, Miguel Górgolas Hernández-Mora, Vadim Pokrovsky, Edgar T Overton, Amy Cutrell

N Engl J Med· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV prevention trial design in an era of effective pre-exposure prophylaxis.
Amy Cutrell, Deborah Donnell, David T Dunn, David V Glidden, Anneke Grobler

HIV Clin Trials· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.
Stephen Gardner, Amy Cutrell, Cindy Elko-Simms, Kimberly Adkison, Robert Hamatake

Liver Int· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.
Cindy H Brothers, Jaime E Hernandez, Amy G Cutrell, Lloyd Curtis, Mounir Ait-Khaled

J Acquir Immune Defic Syndr· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistics 101. A basic guide to the numbers game behind research.
Amy G Cutrell

Posit Aware· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abacavir and the potential risk of myocardial infarction.
Amy Cutrell, Cindy Brothers, Jane Yeo, Jamie Hernandez, Didier Lapierre

Lancet· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir.
Amy G Cutrell, Jaime E Hernandez, Julie W Fleming, Mark T Edwards, Martha Anne Moore

Ann Pharmacother· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factor analysis of hypersensitivity reactions to abacavir.
William Symonds, Amy Cutrell, Mark Edwards, Helen Steel, Bill Spreen

Clin Ther· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
Mounir Ait-Khaled, Abdelrahim Rakik, Philip Griffin, Amy Cutrell, Margaret A Fischl

Antivir Ther· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis